Trial Profile
A Phase 1 Target Occupancy PET Study of Xanamem
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 30 Jan 2024
Price :
$35
*
At a glance
- Drugs UE 2343 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- 24 Jan 2024 According to an Actinogen Media Release, study results support exploring doses of <-10 mg in clinical trials, consistent with the on-going XanaCIDD (Phase 2a, depression) and XanaMIA (Phase 2b, Alzheimer's disease) trials.
- 24 Jan 2024 According to an Actinogen Media Release, authors concluded that a dose level of 10 mg daily achieved near saturation of the enzyme target, meaning that higher doses achieved little additional occupancy.
- 24 Jan 2024 According to an Actinogen Media Release, positive data from this study published in Journal of Alzheimer's Disease.